Batch Due Diligence Platform
Score your entire pipeline in days, not months. Batch due diligence for investment teams screening 5–50+ opportunities. From $2,500 per company.
The Challenge
You see hundreds of deals. Traditional due diligence takes 4–6 weeks per company.
Reviewing even 10 companies in parallel means months of team time. Your best deals close while you're still building the business case.
Different team members assess risk differently. Without a standard framework, you're not comparing apples to apples across your pipeline.
Regulatory, clinical, and technical red flags emerge late in diligence. By then, you've already invested time and capital into the wrong opportunities.
Hiring dedicated clinical and technical experts is expensive. You need intelligent triage without building a 10-person in-house team.
The Solution
Four steps from submission to ranked portfolio intelligence
CSV, spreadsheet, or company list. Include basic info: company name, vertical, stage, and what matters to you (clinical readiness, IP strength, etc.).
Vertical assignment, stage estimation, risk bucket. Each company gets categorized by therapeutic area and development maturity.
Proprietary categories scored simultaneously across clinical, regulatory, technical, and commercial domains using our multi-domain assessment framework.
All companies ranked by composite score. Go/No-Go flags per company. Portfolio heat map showing where clusters of risk lie.
Live Demo
Watch Vantage transform an unscored pipeline into ranked, actionable intelligence
| Company | Score | Status |
|---|
Investment Tiers
Pay per company, with volume discounts as your batch grows
Quick Screen
$2,500
per company
5–10 companies per batch
Deal Flow
$2,000
per company
10–25 companies per batch
Enterprise
$2,000
per company
25–50+ companies per batch
Annual Program
$65K–$100K
per year
Quarterly batches + retainer
Traditional advisory: $50,000–$150,000 per company
$2,500–$2,000Vantage deal flow evaluation per company
20–60x cost advantage
Your Deliverables
Per company assessment plus portfolio-level dashboard
Single aggregated score (1–10 scale) with risk classification: Go, Yellow Flag, or No-Go. Includes confidence bands per scoring category.
Proprietary domain-level scores across clinical, regulatory, technical, and commercial dimensions — each calibrated to your specific vertical.
Your top 3 risks (clinical, regulatory, commercial). Your top 3 strengths. Clear flags for immediate attention.
1–2 page executive summary with Go/No-Go call, next-step guidance, and confidence level for investment decision-makers.
All companies ranked side-by-side. Portfolio heat map showing concentration of risk. Visual comparison for faster decision-making.
Every score grounded in federal data sources. Transparent methodology per category. Verifiable and defensible for partner meetings.
Investment Teams
Batch triage for three key buyer types
Pre-screen your funnel before partner meetings. Rank 15 companies down to your top 5 in days. Shared framework across all LPs.
Evaluate platform targets and bolt-on acquisition candidates in parallel. Screen 30 companies. Identify which fit your thesis.
Assess cohort readiness pre-demo day. Benchmark portfolio companies. Identify where founders need help. Track progress over time.
Our Advantage
Not just batch processing. Clinical judgment at scale.
Every batch reviewed by Dr. Arvind Ravinutala (MD). Clinical context that models miss — adoption barriers, regulatory timing, reimbursement nuance.
Aswini Ravinutala (BME) brings device design, manufacturing readiness, and technical feasibility analysis to every company in your batch.
Scores grounded in federal regulatory databases, clinical evidence, IP records, and market intelligence. Every score is citeable and defensible.
Batch processing reduces cost per company without sacrificing depth. 24–48 hours for 5–50+ companies. Impossible with traditional advisory.
Competitive Advantage
While others are in week 4 of diligence on 2 companies, you've ranked 20.
4–6 weeks per company
$50K–$150K per deal analyzed
Sequential. One firm, one company at a time.
24–48 hours for entire batch
$2,500–$2,000 per company
Parallel. All companies scored simultaneously.
Why Investment Teams Trust Us
Clinical insight. Engineering rigor. Scalable due diligence.
Arvind Ravinutala, MD, brings 15+ years of clinical informatics experience. Every assessment includes reimbursement reality and patient adoption insights.
Aswini Ravinutala, BME, CTO at Spiro Medical. Deep expertise in device design, regulatory quality systems, and manufacturing complexity.
Every score is grounded in verifiable federal and peer-reviewed data sources. Your reports are defensible in board meetings and partner discussions.
Submit your deal list. Get ranked scores in 24–48 hours. Make better investment decisions faster.